Cost effectiveness of adding folinic acid to fluorouracil plus levamisole as adjuvant chemotherapy in patients with colon cancer in Germany

PharmacoEconomics

Volumn 21, Issue 10, 2003, Pages 709-719

  Monz, Brigitta U M ^a   König, Hans Helmut ^a   Leidl, Reiner ^a   Staib, Ludger ^a   Link, Karl Heinrich ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; LEVAMISOLE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; ECONOMIC ASPECT; FEMALE; GERMANY; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; COST-BENEFIT ANALYSIS; FEMALE; FLUOROURACIL; FOLIC ACID; GERMANY; HUMANS; LEVAMISOLE; MALE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; QUALITY-ADJUSTED LIFE YEARS;

EID: 0041742228     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200321100-00003     Document Type: Article

References (35)

1. Becker N. Epidemiologie von Tumoren. In: Schmoll HJ, Hoeffken K, Possinger K, editors. Kompendium der Internistischen Onkologie. 3nd ed. Berlin: Springer Verlag, 1999: 173-215
2. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322: 352-8
3. NIH Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990 Sep 19; 264 (11): 1444-50
4. O'Connell MJ, Mailliard JA, Kahn MJ, et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997; 15: 246-50
5. O'Connell MJ, Laurie JA, Kahn M, et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 1998; 16 (1): 295-300
6. Moore HCF, Haller DG. Adjuvant therapy of colon cancer. Semin Oncol 1999; 26 (5): 545-55
7. QUASAR Collaborative Group. Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. Lancet 2000; 355: 1588-96
8. Kerr DJ, Gray R, McConkey C, et al. Adjuvant chemotherapy with 5-fluorouracil, L-folinic acid and levamisole for patients with colorectal cancer: non-randomised comparison of weekly versus four-weekly schedules: less pain, same gain. Ann Oncol 2000; 11: 947-55
9. IMPACT. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International multicentre pooled analysis of colon cancer trials (IMPACT) investigators. Lancet 1995; 345: 939-44
10. Link KH, Staib L, Bernhart H, et al. Acceptance and toxicity of postoperative adjuvant therapy in colon and rectal cancers. Onkologie 1997; 20: 235-8
11. Link KH, Kreuser ED, Staib L, et al. Increase of the adjuvant treatment benefit in advanced resectable colon cancer with systemic treatment of 5-FU plus levamisole: 5-year survival rates and results of the FOGTI-trial [abstract]. Abstracts of the 25th German Cancer Congress; 2002 Mar 10-14; Berlin, Germany. J Cancer Res Clin Oncol 2002; 128 Suppl. 1: S84
12. Staib L, Link KH, Beger HG. Toxicity and effects of adjuvant therapy in colon cancer: results of the German prospective, controlled randomized multicenter trial FOGT-1. J Gastrointest Surg 2001; 5: 275-81
13. Wolmark N, Rockette H, Mamounas E, et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin and levamisole in Patients with Dukes' B and C carcinoma of the colon: results from national surgical adjuvant breast and bowel project C-04. J Clin Oncol 1999; 17: 3553-9
14. Mamounas E, Wieand S, Wolmark N, et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four national surgical adjuvant breast and bowel project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 1999; 17: 1349-55
15. Arnold M, Paffrath D, editors. Krankenhaus-report '98. Stuttgart: Fischer Verlag, 1998. (Database on disk)
16. Arnold M, Litsch M, Schwartz FW, editors. Krankenhaus-report '99. Stuttgart: Schattauer Verlag, 2000. (Database on disk)
17. Einheitlicher Bewertungsmasstab. Dienstauflage der Kassenaerztlichen Vereinigung. Cologne: Deutscher Aerzteverlag, 1999
18. Rote Liste® 2000. Available from URL: http://www.rote-liste.de [Accessed 2000 Oct 19-20]
19. Lin DY, Feuer EJ, Etzioni R, et al. Estimating medical costs from incomplete follow-up data. Biometrics 1997; 53: 419-43
20. Brown ML, Riley GF, Potosky AL. Obtaining long-term disease specific costs of care - application to Medicare enrollees diagnosed with colorectal cancer. Med Care 1999; 37: 1249-59
21. Henne-Bruns D, Boll PH, Marxsen J, et al. Modellversuch "Operative Onkologie": finanzierungskonzept komplexer onkologischer therapieverfahren. Gesundheitsoekonomie und Qualitätsmanagement 2000; 5: 129-33
22. Willan AR, Lin DY. Incremental net benefit in randomised clinical trials. Star Med 2001; 20: 1563-74
23. Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
24. Hannoveraner Konsensusgruppe. Deutsche empfehlungen zur gesundheits-oekonomischen evaluation. Revidierte fassung des Hannoveraner konsens. Med Kiln 2000; 95: 52-5
25. Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998; 13 (4): 397-409
26. Moertel CG, Fleming TR, Macdonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995; 122: 321-6
27. International Agency for Research on Cancer (IARC). Available from URL: http://www-dep.iarc.fr/eucan/eucan.htm [Accessed 2001 Jan 8]
28. Miller DK, Homan SM. Determining transition probabilities: confusion and suggestions. Med Decis Making 1994; 14: 52-8
29. Sculpher M, Fenwick E, Claxton K. Assessing quality in decision analytic cost-effectiveness models: a suggested framework and example of application. Pharmacoeconomics 2000; 17 (5): 461-77
30. Earle CC, Chapman RH, Baker CS, et al. Systematic overview of cost-utility assessments in oncology. J Clin Oncol 2000; 18: 3302-17
31. Ness RM, Holmes AM, Klein R, et al. Utility valuations for outcome states of colorectal cancer. Am J Gastroenterol 1999; 94: 1650-7
32. Ness RM, Holmes AM, Klein R, et al. Outcome states of colorectal cancer: identification and description using patient focus groups. Am J Gastroenterol 1998; 93: 1491-7
33. Norum J, Vonen B, Olsen JA, et al. Adjuvant chemotherapy (5-fluorouracil and levamisole) in Dukes' B and C colorectal carcinoma: a cost-effectiveness analysis. Ann Oncol 1997; 1: 65-70
34. Ramsey SD, Andersen MR, Etzioni R, et al. Quality of life in survivors of colorectal carcinoma. Cancer 2000; 88: 1294-303
35. Tengs T, Adams M, Pliskin J, et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal 1995; 15: 369-90